We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ADCETRIS Takeda Pharmaceuticals Australia Pty Ltd
Product name
ADCETRIS
Accepted date
Jan-2025
Active ingredients
Brentuximab vedotin
Proposed indication
ADCETRIS is for the treatment of adult patients with previously untreated Hodgkin Lymphoma, in combination with a cocktail of other anti-cancer drugs.
Application type
C (new indication)
Publication date
Jan-2025